The Fly | INMD

InMode

· INMD

Dashboard

Financials

KPIs

Ratios

Transcripts

Valuation

Yesterday

InMode confirms receipt of unsolicited $16.20 per share takeover proposal

INMD

Yesterday, 8:42 AM

Over a week ago

InMode names Moshik Itzkovich as CFO, succeeding Yair Malca

INMD

May 20, 7:05 AM

InMode price target lowered by $3 at Baird, here's why

INMD

May 7, 7:13 AM

InMode price target lowered by $2 at Barclays

INMD

May 7, 5:32 AM

InMode CFO Yair Malca steps down

INMD

May 6, 7:09 AM

InMode sees FY26 adjusted EPS $1.33-$1.38, consensus $1.45

INMD

May 6, 7:07 AM

InMode reports Q1 adjusted EPS 25c, consensus 30c

INMD

May 6, 7:06 AM

InMode announces new share repurchase program

INMD

Mar 13, 7:01 AM

InMode's independent transaction committee determines to discontinue process

INMD

Feb 23, 7:11 AM

InMode price target raised by $1 at Baird, here's why

INMD

Feb 11, 7:03 AM

InMode sees 2026 non-GAAP EPS $1.43-$1.48, consensus $1.64

INMD

Feb 10, 7:06 AM

InMode reports Q4 non-GAAP EPS 46c, consensus 42c

INMD

Feb 10, 7:05 AM

InMode says 'currently evaluating potential strategic alternatives'

INMD

Feb 2, 7:05 AM

Unusually active option classes on open January 29th

Jan 29, 9:40 AM

Steel Partners presents $18.00 per share offer to acquire 51% of InMode

INMD

Jan 28, 5:33 PM

What You Missed On Wall Street On Monday

+30

Jan 26, 4:23 PM

Midday Fly By: Minnesota CEOs call for deescalation, Nvidia invests in CoreWeave

+29

Jan 26, 11:59 AM

InMode in talks to be sold for $1.1B to investment fund, Calcalist reports

INMD

Jan 26, 8:56 AM

InMode price target lowered by $1 at Canaccord, here's why

INMD

Dec 17, 7:15 AM

InMode price target lowered by 25c at UBS

INMD

Nov 6, 8:29 AM

InMode backs FY25 adjusted EPS view $1.55-$1.59, consensus $1.58

INMD

Nov 5, 7:08 AM

InMode reports Q3 adjusted EPS 38c, consensus 35c

INMD

Nov 5, 7:07 AM

Needham medtech & diagnostics analysts hold analyst/industry conference call

Oct 16, 4:55 AM

InMode shares drop after FDA notes 'risks' of RF microneedling devices

INMD

Oct 15, 11:12 AM

Proprietary Technology & Innovation: * Inmode consistently develops and patents cutting-edge, minimally invasive aesthetic and medical solutions, maintaining a technological lead in the market.

Recurring Revenue Model: * Their devices often utilize disposable handpieces and consumables, generating predictable, high-margin recurring revenue streams post-initial device sale.

Extensive IP Portfolio: * A robust portfolio of patents protects their unique technologies, creating significant barriers to entry for competitors and securing their market position.

Intense Competition Risk: Inmode operates in a highly competitive market for medical aesthetic devices, which could negatively impact its market share, pricing power, and profitability.

Regulatory Approval Challenges: The company's products require stringent regulatory approvals from bodies like the FDA and similar international agencies, and delays or failures to obtain or maintain these could restrict product sales.

Product Liability Exposure: Inherent risks associated with the use of medical devices could lead to product liability claims, lawsuits, and significant financial and reputational damages.